[Development of heart hypertrophy in hypertension]

Kardiologiia
|April 1, 1983
PubMed

Insights

Essential hypertension treatment reduced left-ventricular hypertrophy by improving blood pressure control and decreasing adrenergic heart influence. This study examined 120 patients with stage I and II hypertension.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Context:

  • Essential hypertension affects a significant portion of the adult population.
  • Left-ventricular muscular hypertrophy is a common complication of untreated hypertension.
  • Understanding the mechanisms of hypertrophy is crucial for effective treatment.

Purpose:

  • To investigate the mechanisms underlying left-ventricular muscular hypertrophy in patients with essential hypertension.
  • To evaluate the impact of hypotensive treatment on electrocardiographic signs of left-ventricular muscular hypertrophy.
  • To determine the relationship between antihypertensive treatment efficacy and changes in arterial pressure and adrenergic influence.

Summary:

  • 120 patients with stage I and II essential hypertension underwent radio- and electrocardiography before and after hypotensive treatment.
  • Two primary mechanisms for left-ventricular muscular hypertrophy were identified: excessive volume in hyperkinetic circulation and excessive pressure in normo- and hypokinetic circulation.
  • Antihypertensive treatment demonstrated efficacy in reducing electrocardiographic signs of left-ventricular muscular hypertrophy, linked to improved blood pressure management and reduced cardiac adrenergic activity.

Impact:

  • Findings elucidate the pathophysiological basis of left-ventricular hypertrophy in hypertension.
  • Demonstrates the therapeutic benefit of antihypertensive interventions on cardiac remodeling.
  • Highlights the importance of comprehensive blood pressure control and modulation of adrenergic tone in managing hypertensive heart disease.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...